ConductScience.org, home

Paper28928126

Chimeric antigen receptor T-cell therapies for multiple myeloma.

Mikkilineni L and 1 other. Blood, 2017. Cited by 185 papers, by iCite.

Cite this record

ConductScience Library. Chimeric antigen receptor T-cell therapies for multiple myeloma. Papers, record 28928126. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28928126

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chimeric antigen receptor T-cell therapies for multiple myeloma.
PubMed
Journal
Blood
PubMed
Year
2017
PubMed
Publication types
Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
185
iCite
Relative citation ratio, by iCite
5.41
iCite
Revised in PubMed
2024-03-29
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mikkilineni LLekha
2Kochenderfer JNJames N

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Receptors, Antigen, T-CellMajor topic
Recombinant Fusion ProteinsMajor topic
T-LymphocytesMajor topic
Antigens, CD19
Humans
Immunotherapy, Adoptive
Neoplastic Stem Cells
Plasma Cells

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
ZIABC011439NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03778346Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T CellsBackground

Source ClinicalTrials.gov

Download CSV of trials

References92

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
122160384B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.Blood2012https://conductscience.org/library/papers/22160384PubMed
228291388Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.J Clin Oncol2017https://conductscience.org/library/papers/28291388PubMed
327207799Toxicities of chimeric antigen receptor T cells: recognition and management.Blood2016https://conductscience.org/library/papers/27207799PubMed
426726943Allogeneic stem cell transplantation for multiple myeloma: is there a future?Bone Marrow Transplant2016https://conductscience.org/library/papers/26726943PubMed
529061640Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.Clin Cancer Res2018https://conductscience.org/library/papers/29061640PubMed
67913116Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule.J Immunol1994https://conductscience.org/library/papers/7913116PubMed
719047103Preclinical characterization of SGN-70, a humanized antibody directed against CD70.Clin Cancer Res2008https://conductscience.org/library/papers/19047103PubMed
825995224Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma.Sci Transl Med2015https://conductscience.org/library/papers/25995224PubMed
96460831Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.J Exp Med1982https://conductscience.org/library/papers/6460831PubMed
1022766978Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.Int J Oncol2012https://conductscience.org/library/papers/22766978PubMed
1124311149Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.Int J Hematol2014https://conductscience.org/library/papers/24311149PubMed
1227270177Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.J Clin Invest2016https://conductscience.org/library/papers/27270177PubMed
1319561539Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.J Immunother2009https://conductscience.org/library/papers/19561539PubMed
1424876563Current concepts in the diagnosis and management of cytokine release syndrome.Blood2014https://conductscience.org/library/papers/24876563PubMed
1516203864Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.J Exp Med2005https://conductscience.org/library/papers/16203864PubMed
1624055823Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Blood2013https://conductscience.org/library/papers/24055823PubMed
1710931011Controversies surrounding the clonogenic origin of multiple myeloma.Br J Haematol2000https://conductscience.org/library/papers/10931011PubMed
1824553386Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med2014https://conductscience.org/library/papers/24553386PubMed
1921830940Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med2011https://conductscience.org/library/papers/21830940PubMed
2027998219How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.J Clin Oncol2016https://conductscience.org/library/papers/27998219PubMed

See all 92 referencesDownload CSV of references

Cited by145

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.

PMIDTitleJournalYearIn PapersSource
42157940Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells.Int J Biol Sci2026https://conductscience.org/library/papers/42157940PubMed
41617828Generation of TCRγδ + T cells from human embryonic stem cells.Sci Rep2026https://conductscience.org/library/papers/41617828PubMed
41455063Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer.Stem Cell Rev Rep2026https://conductscience.org/library/papers/41455063PubMed
41303706State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens.Int J Mol Sci2025https://conductscience.org/library/papers/41303706PubMed
41228344
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T).
Cancers (Basel)2025https://conductscience.org/library/papers/41228344PubMed
40627450CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS.JCI Insight2025https://conductscience.org/library/papers/40627450PubMed
40619794Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.Balkan Med J2025https://conductscience.org/library/papers/40619794PubMed
40606990Cardiovascular adverse effects of immunotherapy in cancer: insights and implications.Front Oncol2025https://conductscience.org/library/papers/40606990PubMed
40433368Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies.Front Immunol2025https://conductscience.org/library/papers/40433368PubMed
40029598Immune Cell Homing Hydrogels for Cancer Immunotherapy.Methods Mol Biol2025https://conductscience.org/library/papers/40029598PubMed
39957814Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.Iran J Med Sci2025https://conductscience.org/library/papers/39957814PubMed
39901537A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy.Anticancer Agents Med Chem2025https://conductscience.org/library/papers/39901537PubMed
39893165Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies.Nat Commun2025https://conductscience.org/library/papers/39893165PubMed
39692978Revolutionizing cancer treatment: the rise of personalized immunotherapies.Discov Oncol2024https://conductscience.org/library/papers/39692978PubMed
39625587CAR T-cell therapy to treat multiple myeloma: current state and future directions.Cancer Metastasis Rev2024https://conductscience.org/library/papers/39625587PubMed
39614361BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.J Transl Med2024https://conductscience.org/library/papers/39614361PubMed
39592597CAR-T cell therapy in Multiple Myeloma: current status and future challenges.Blood Cancer J2024https://conductscience.org/library/papers/39592597PubMed
39290982Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review.Ther Adv Hematol2024https://conductscience.org/library/papers/39290982PubMed
38964917[Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy].Zhonghua Xue Ye Xue Za Zhi2024https://conductscience.org/library/papers/38964917PubMed
38651157Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.Front Oncol2024https://conductscience.org/library/papers/38651157PubMed

See all 145 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CXADRP1653108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene
SDC16382PubTator's text mininghttps://conductscience.org/library/genes/6382NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28928126

GET https://conductscience.org/api/papers/v1/28928126/references?page=2